References
ASCEND Study Collaborative Group, Bowman L, Mafham M et al (2018) Effects of aspirin for primary prevention in persons with diabetes mellitus. NEJM 379(16):1529–1539
Ridker PM (2018) Should aspirin be used for primary prevention in the post-statin era? NEJM 379(16):1572–1574
ASCEND Study Collaborative Group, Bowman L, Mafham M et al (2018) Effects of n-3 fatty acid supplements in diabetes mellitus. NEJM 379(16):1540–1550
Maurer MS, Schwartz JH, Gundapaneni B et al (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. NEJM 379(11):1007–1016
Quarta CC, Solomon SD (2018) Stabilizing transthyretin to treat ATTR cardiomyopathy. NEJM 379(11):1083–1084
Obadia JF, Messika-Zeitoun D, Leurent G et al (2018) Percutaneous repair or medical treatment for secondary mitral regurgitation. NEJM. https://doi.org/10.1056/NEJMoa1805374
Thiele H, Akin I, Sandri M et al (2018) One-year outcomes after PCI strategies in cardiogenic shock. NEJM 379(18):1699–1710
Thiele H, Akin I, Sandri M et al (2017) PCI strategies in patients with acute myocardial infarction and cardiogenic shock. NEJM 377(25):2419–2432
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Steen, D.L. Highlights from the 2018 European Society of Cardiology Congress in Munich, Germany. J Thromb Thrombolysis 47, 312–315 (2019). https://doi.org/10.1007/s11239-019-01810-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-019-01810-3